COST-UTILITY ANALYSIS OF LIRAGLUTIDE VERSUS GLIMEPIRIDE AS ADD-ON TO METFORMIN IN TYPE 2 DIABETES PATIENTS IN CHINA

Lan Gao, Fei-Li Zhao, Shu‐Chuen Li

International Journal of Technology Assessment in Health Care · 2012 · 33 citations · 33 references

Abstract

Long-term projections indicated that liraglutide was associated with increased life expectancy, QALYs, and reduced complication incidences comparing with glimepiride. When the UK cost of liraglutide was discounted by 38 percent, liraglutide would be a cost-effective option in China from the healthcare system perspective using the 3X GDP/capita per QALY as the WTP threshold.

References

33